

News : inexpensive sustained dexamphetamine therapy 'for the patient who is tired all day', 'for day-long appetite control' : dexten ion-resin-bonded dexamphetamine, barbidex dexten plus phenobarbitone / Clinical Products Ltd.

Contributors

Clinical Products, Ltd.

Publication/Creation

Richmond, Surrey : Clinical Products, [1957?]

Persistent URL

<https://wellcomecollection.org/works/cyg9z544>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

NEWS

**INEXPENSIVE
SUSTAINED DEXAMPHETAMINE THERAPY**

'for the patient who is tired all day'

'for day-long appetite control'

'IONEX - TABS'

WORK ROUND THE CLOCK




'dexten'

ION - RESIN - BONDED DEXAMPHETAMINE

'barbidex'

DEXTEN PLUS PHENOBARBITONE

HOW 'ION-EX' ION-EXchange TABLETS DIFFER FROM ORDINARY AND 'LAYERED' TABLETS



In 'ionex-tabs' the sustained action is inherent in the drug resinate and does not depend on enteric coating. Controlled ionic exchange feeds the therapeutic agent into the blood stream evenly and without interruption for 10 to 12 hours independent of physiological factors.

WHAT IS SUSTAINED ACTION THERAPY

Sustained action therapy is a modern concept conveying a constant uniform absorption of a therapeutic agent supplied in one dose and sustaining an even optimum drug level in the tissues for 10 to 12 hours without producing excessive peak concentrations thus avoiding side-effects.

PRESENT METHODS OF ACHIEVING DELAYED OR SUSTAINED ACTION

Most long-acting oral preparations depend upon the use of "layered" tablets or a mixture of variously sized granules. In all such cases the delayed or sustained action is obtained by varying the disintegration times of the separate layers or granules by *enteric-coating*. Such methods are liable to be uncertain in action because release is influenced by physiological factors, such as peristalsis and the activity of the gastro-intestinal fluid, which have considerable individual variations.

WHAT ARE THE ADVANTAGES OF 'IONEX-TABS'

'Ionex-tabs' consist of an active pharmacological agent bonded to an ion exchange resin. When the resinate is ingested, an ionic exchange takes place; the drug is liberated and the cations, e.g. H^+ sodium or potassium are bonded to the resin. The process takes time and by using appropriate resins has been adjusted to produce what is considered to be the *optimum release rate* for each drug, ranging between 8 and 10 hours. The release rate is not affected by hydrogen-ion concentration or enzyme activity as the ionic concentrations in the gastro-intestinal tract are remarkably constant.

The fundamental advantage of 'ionex-tabs' is that they damp down the fluctuations of concentration in the tissue fluids of ingested pharmacological agents. To be more precise they inhibit excessive concentrations which are responsible for toxic reactions and also prevent falls in concentration to ineffective levels.

Both aspects of this damping action are important. Excessive concentrations which, in spite of their tendency to aggravate side-effects, are often accepted for the sake of convenience in order to secure a prolonged action, are unnecessary. Subliminal dosages do not occur. The losses due to drug destruction and excretion are constantly being restored. An *uninterrupted* as opposed to an *intermittent* pharmacological action results, lasting for 10 to 12 hours independent of varying physiological factors.

'Ionex-tabs' are an ideal vehicle for continuously conveying pharmacological supplements or correctives to the site of a disordered metabolic process.

'dexten'**ionex-tabs**

**FOR DAY-LONG APPETITE SUPPRESSION
FOR THE PATIENT WHO IS TIRED ALL DAY**

Advantages of 'dexten' 'ionex-tabs'

1. Even, uninterrupted therapeutic effect lasting 10 to 12 hours with ONE MORNING DOSE.
2. Low N.H.S. Basic cost. AVERAGE COST OF TREATMENT: 1d. A DAY.
3. More effective and better tolerated than ordinary Dexamphetamine tablets.

PHARMACOLOGY. Dexamphetamine acts both centrally and peripherally and stimulates the cerebral cortex with consequent pronounced mood elevation. Like all sympathomimetic drugs it relaxes the gastric muscles thereby relieving "hunger pains".

INDICATIONS. 'dexten' 'ionex-tabs' are indicated in all conditions where amphetamine therapy is normally required, such as an appetite control, as a stimulant where overwork or conditions of stress have induced mental depression and/or physical fatigue, Parkinsonian syndrome, hypothyroidism, hypotension, etc. Where concomitant sedation is desirable 'barbidex' is indicated.

FORMULA. 10 mg. Dexamphet. Sulph. (as resinate).

'barbidex'**ionex-tabs**

**FOR DAY-LONG UNINTERRUPTED RELIEF
OF ANXIETY AND DEPRESSION
FOR DAY-LONG APPETITE CONTROL**

Advantages of 'barbidex' 'ionex-tabs'

1. Day-long "normalizing effect" upon both anxiety and depression and day-long appetite suppression with just ONE MORNING DOSE.
2. Low N.H.S. Basic cost. AVERAGE COST OF TREATMENT: 1½d. A DAY.
3. More effective and better tolerated than ordinary tablets.

PHARMACOLOGY. In 'barbidex' 'ionex-tabs' dexamphetamine and phenobarbitone act in day-long harmony, "normalizing" extreme swings of anxiety and depression, and suppression of appetite. The combined effect is free from both the excitation which may be caused by the action of dexamphetamine and from the familiar depressing effect of barbiturates.

INDICATIONS. 'barbidex' 'ionex-tabs' are indicated in all conditions where dexamphetamine therapy with concomitant sedation is normally required such as obesity in the nervous patient, emotional instability and anxiety states, reactive depression and in psychiatry as a valuable adjunct to psychotherapy. 'barbidex' should be prescribed in preference to 'dexten' in all cases hypersensitive to the stimulating action of dexamphetamine.

FORMULA. 10 mg. Dexamphet. Sulph. (as resinate), 1 gr. Phenobarbitone.

ADMINISTRATION AND DOSAGE

One 'dexten' or 'barbidex' 'ionex-tab' on rising or at breakfast. In view of the superior clinical results obtained, begin with half a tablet daily. The response to this dose will be the best guide to the optimal need of the patient. 'dexten' and 'barbidex' should not be given after 10 a.m.

SIDE-Reactions, if any, may be largely avoided by dosage adjustment, for which purpose the tablets are quarter-scored.

CONTRA-INDICATIONS, 'dexten' and 'barbidex' 'ionex-tabs', as all amphetamine preparations, should be used with caution in thyrotoxicosis, chronic insomnia and known idiosyncrasy to sympathomimetic amines.

'dexten' and 'barbidex'

THE CLINICAL PICTURE

Clinical study of 21 patients treated and observed with **'dexten'** and 32 with **'barbidex'** for from 2 to 8 weeks, clearly indicates that results can be obtained with ONE **'dexten'** or **'barbidex'** 'ionex-tab' superior to those from a higher dose of dexamphetamine (with or without barbiturates respectively) in ordinary tablet form.

The results may be summarised as follows:—

1. The shortest duration of therapeutic effect was 7 hours and the longest 11—12 hours.
2. In all patients the action was smooth. None complained of any variation in effect which might have indicated a changing rate of absorption or utilization of the drug.
3. The average loss of weight of 14 controlled cases was 6 lbs. in four weeks. One patient on **'barbidex'** lost 7 lbs. in the first week and another on **'dexten'** lost 12 lbs. in 4 weeks.
4. Side-reactions appeared to be fewer and less severe than those resulting from an even smaller dose of the same drugs in ordinary tablet form, and during the course of treatment were largely eliminated by dosage adjustment.

BIBLIOGRAPHY AND REFERENCES

- Abrahams, Sir A., Linnell W. H. (Prof.) 1957 (in the Press)
Kekwick, A. (Prof.), Middlesex Hospital, London (Personal Communication)
Livingston S. et. alia J. Pediat. 1948, 32, 490
Marguiles, H., British Medical Journal, 1957, 1, 1531.
Newbold, G., British Medical Journal, 1957, 1, 1303.
Saunders L., et al., Journal of Pharmacy and Pharmacology Nov. 1956, p. 975
S. C. Freed, J. W. Keating & E. E. Hays, Annals of Int. Med. 1956, 44, 1136
Strom-Olsen R., Lancet 1950, ii, 133
Taylor Z. E., New. Eng. J. Med. i/1941, 197



'dexten'

'ION-EX' BRAND

sustained action tablets

Issued in

SAFETY CONTAINERS OF 30 tablets

BOTTLES OF 250 tablets

BASIC N.H.S. COST 30 tablets 2/6d.

(AVERAGE COST OF TREATMENT 1d. A DAY)



'barbidex'

'ION-EX' BRAND

sustained action tablets

Issued in

SAFETY CONTAINERS OF 30 tablets

BOTTLES OF 250 tablets

BASIC N.H.S. COST 30 tablets 3/10d.

(AVERAGE COST OF TREATMENT 1½d. A DAY)

Samples and literature available on request.

**THE
SAFETY
CONTAINER**

To prevent accidents to children **'dexten'** and **'barbidex'** 'ionex-tabs' are issued in specially designed SAFETY CONTAINERS which a young child cannot open.

ANOTHER 'ION-EX' PRODUCT:

'asmapax' tablets

provide 10 to 12 hours prophylaxis in Bronchial Asthma.

See separate leaflet.

Issued by:

RESEARCH DEPT.
CLINICAL PRODUCTS LTD.
RICHMOND, SURREY, ENGLAND

